May 07, 2019

Working

Participants' recruitment and samples collection

PLOS One

Barbara Rizzacasa[1], Elena Morini[1], Ruggiero Mango[2], Chiara Vancheri[1], Simone Budassi[2], Gianluca Massaro[2], Sara Maletta[1], Massimiliano Macrini[2], Silvio D'Annibale[3], Francesco Romeo[4], Giuseppe Novelli[1], Francesca Amati[5]

[1][Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy], [2][Complex Operative Unit of Cardiology (UOC), Policlinic Tor Vergata, Rome, Italy], [3][Department of System Medicine, University of Rome Tor Vergata, Rome, Italy], [4][Complex Operative Unit of Cardiology (UOC), Policlinic Tor Vergata, Rome, Italy; Department of System Medicine, University of Rome Tor Vergata, Rome, Italy], [5][Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Department of Human Sciences and Quality of Life Promotion, University San Raffaele, Rome, Italy]

dx.doi.org/10.17504/protocols.io.zpvf5n6

Francesca Amati

ABSTRACT

A total of 99 patients has been enrolled to study circulating microRNAs, as diagnostic biomarkers, in patients with chronic stable coronary artery disease (CAD) and with acute myocardial infarction (AMI). For each patient, we have collected 10 mL of whole blood. All the samples have been processed maintaining the same conditions and timing. The samples with hemolysis and clots have been excluded from the study.

EXTERNAL LINK

https://doi.org/10.1371/journal.pone.0216363

THIS PROTOCOL ACCOMPANIES THE FOLLOWING PUBLICATION

Rizzacasa B, Morini E, Mango R, Vancheri C, Budassi S, Massaro G, Maletta S, Macrini M, D'Annibale S, Romeo F, Novelli G, Amati F (2019) MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study. PLoS ONE 14(5): e0216363. doi: 10.1371/journal.pone.0216363

MATERIALS

NAME	CATALOG #	VENDOR	CAS NUMBER	RRID
K2EDTA Vacutainer Tubes	366643	Bd		

Partecipant's recruitment

1 A total of 99 patients has been enrolled for our study: 61 patients with chronic stable coronary artery disease (CAD) and 38 patients after a myocardial infarction event (AMI). For each patient, we took a blood sample.

2 All the samples, maintained at room temperature, have been processed within 4h from the blood's withdrawal.Before the processing, all the sample have been controlled to exclude the presence of hemolysis and clots.

Sample collection

3 • 10mL of whole blood have been collected in tube with K2 EDTA anticoagulant at the time of hospitalization from the 61 patients of CAD group;

4 • 10mL of whole blood have been collected in tube with K2 EDTA anticoagulant from the 38 patients of AMI group within 24 hours from the onset of myocardial event (AMI_T0 group);

5 • 10 ml of whole blood have been collected in tube with K2 EDTA anticoagulant at 6 months post-AMI from 11 patients, previous recruited after a myocardial infarction event, who accepted to participate (AMI_T1 group).